The overexpression of MMP2 was reported previously in several cancer tissues, and the inhibition of MMP2 function by halofuginone resulted in significant reduction of vascular functionality, decreased vascular density and less tumor size in VHL PCC in vivo models [76]. This evidence concerns the gene VHL and adrenal gland pheochromocytoma.